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Study design
The study was a randomized, placebo-controlled, double-blinded trial carried out in a single centre. The duration of follow-up appears to have been until discharge with no loss to follow-up. The study sample did not consume milk or solid food for at least 6 hours before operation: clear fluids were allowed until 3 hours before induction. The study did not control the volume of fluid children ingested in the 3 hours before surgery. A random number generator was used to assign each child prospectively to receive dexamethasone, ondansetron or saline placebo. An anaesthetist, not otherwise involved in patient care, prepared the study drugs to a fixed volume of 5 ml, to maintain the double-blind nature of the study. Intraoperative i.v. fluid management consisted of administration of lactated Ringer?s solution sufficient to correct half of the preoperative fluid deficit in the first hour, followed by maintenance fluids according to body weight. After operation, all children were transported to the post-anaesthesia care unit (PACU). The anaesthetist who provided intraoperative care assessed post-anaesthetic recovery using the modified Aldrete scoring system. Time to achieve complete recovery (score 10) was recorded for all children. The criteria for discharge from PACU to ward included stable vital signs, adequate pain control, and no nausea and vomiting in the first 2 hours after surgery. Children who had PONV and pain in the first 2 hours of stay were observed in PACU until they had remained free of PONV and pain for an hour.
Analysis of effectiveness
The principle used in the analysis of effectiveness appears to have been intention to treat. The PACU and ward nursing staff, who were aware of the nature of the study but blinded to the study drug, recorded episodes of PONV for the first 24 hours after the operation. A numeric scoring system for PONV was used (0 = no nausea or vomiting, 1 = nausea but no vomiting, 2 = vomiting once in 30 minutes or more, 3 = persistent nausea (longer than 30 min) or two or more vomits in 30 minutes). In this trial, the authors used parental assessment scores of the child's perioperative experience, duration of PACU stay, and fast tracking time as true outcome measures. Any child having a PONV score of 3 was considered to have severe PONV and was treated with metoclopramide 150 micro g/kg i.v. as a rescue antiemetic. The time to achieve eligibility for fast tracking (fast tracking time, FTT) was calculated as the time from the discontinuation of anaesthesia to the time at which the child had a patent airway without support, no PONV, no pain and a recovery score of 10. At the end of 24 hours after surgery, the primary caretaker was asked to give a global assessment of their satisfaction over the entire postoperative experience of the child (parental satisfaction score) using an 11-point verbal numeric scoring system (0 = not at all satisfied, 10 = fully satisfied). Side-effects were also recorded. The study groups were comparable in terms of baseline demographic and prognostic characteristics.
Effectiveness results
The effectiveness results were as follows:
The incidence and severity of PONV in the first 24 hours were significantly less in the dexamethasone and ondansetron groups than in the placebo group (p<0.05).
The incidence (p=0.04) and severity (p=0.03) of PONV at the 6-24 hour epoch were significantly less in the dexamethasone group than in the ondansetron group. The incidence of PONV was 33.3% in the ondansetron group, 24.4% in the dexamethasone group and 75.6% in the placebo group.
Recovery time (p=0.07), fast tracking time (p=0.6), and parental satisfaction scores (p=0.08) were comparable in both the ondansetron and the dexamethasone group.
Ondansetron and dexamethasone were statistically comparable for true, therapeutic outcome measures and side-effects.
Ondansetron and dexamethasone groups had significantly higher parental satisfaction scores than the placebo group, (p<0.0001).
